Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Methylation-Mediated Silencing of <i>RBP7</i> Promotes Breast Cancer Progression through PPAR and PI3K/AKT Pathway

Methylation-Mediated Silencing of RBP7 Promotes Breast Cancer Progression through PPAR and... Retinoid-binding protein7 (<i>RBP7</i>) is a member of the cellular retinol-binding protein (CRBP) family, which is involved in the pathogenesis of breast cancer. The study aims to illustrate the prognostic value and the potential regulatory mechanisms of <i>RBP7</i> expression in breast cancer. Bioinformatics analysis with the TCGA and CPTAC databases revealed that the mRNA and protein expression levels of <i>RBP7</i> in normal were higher compared to breast cancer tissues. Survival analysis displayed that the lower expression of <i>RBP7,</i> the worse the prognosis in ER-positive (ER<sup>+</sup>) breast cancer patients. Genomic analysis showed that low expression of <i>RBP7</i> correlates with its promoter hypermethylation in breast cancer. Functional enrichment analysis demonstrated that downregulation of <i>RBP7</i> expression may exert its biological influence on breast cancer through the PPAR pathway and the PI3K/AKT pathway. In summary, we identified <i>RBP7</i> as a novel biomarker that is helpful for the prognosis of ER<sup>+</sup> breast cancer patients. Promoter methylation of <i>RBP7</i> is involved in its gene silencing in breast cancer, thus regulating the occurrence and development of ER<sup>+</sup> breast cancer through the PPAR and PI3K/AKT pathways. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Oncology Hindawi Publishing Corporation

Methylation-Mediated Silencing of <i>RBP7</i> Promotes Breast Cancer Progression through PPAR and PI3K/AKT Pathway

Methylation-Mediated Silencing of <i>RBP7</i> Promotes Breast Cancer Progression through PPAR and PI3K/AKT Pathway

Journal of Oncology , Volume 2022 – Oct 13, 2022

Abstract

Retinoid-binding protein7 (<i>RBP7</i>) is a member of the cellular retinol-binding protein (CRBP) family, which is involved in the pathogenesis of breast cancer. The study aims to illustrate the prognostic value and the potential regulatory mechanisms of <i>RBP7</i> expression in breast cancer. Bioinformatics analysis with the TCGA and CPTAC databases revealed that the mRNA and protein expression levels of <i>RBP7</i> in normal were higher compared to breast cancer tissues. Survival analysis displayed that the lower expression of <i>RBP7,</i> the worse the prognosis in ER-positive (ER<sup>+</sup>) breast cancer patients. Genomic analysis showed that low expression of <i>RBP7</i> correlates with its promoter hypermethylation in breast cancer. Functional enrichment analysis demonstrated that downregulation of <i>RBP7</i> expression may exert its biological influence on breast cancer through the PPAR pathway and the PI3K/AKT pathway. In summary, we identified <i>RBP7</i> as a novel biomarker that is helpful for the prognosis of ER<sup>+</sup> breast cancer patients. Promoter methylation of <i>RBP7</i> is involved in its gene silencing in breast cancer, thus regulating the occurrence and development of ER<sup>+</sup> breast cancer through the PPAR and PI3K/AKT pathways.

Loading next page...
 
/lp/hindawi-publishing-corporation/methylation-mediated-silencing-of-i-rbp7-i-promotes-breast-cancer-ttemEIJ0UM

References (71)

Publisher
Hindawi Publishing Corporation
ISSN
1687-8450
eISSN
1687-8469
DOI
10.1155/2022/9039110
Publisher site
See Article on Publisher Site

Abstract

Retinoid-binding protein7 (<i>RBP7</i>) is a member of the cellular retinol-binding protein (CRBP) family, which is involved in the pathogenesis of breast cancer. The study aims to illustrate the prognostic value and the potential regulatory mechanisms of <i>RBP7</i> expression in breast cancer. Bioinformatics analysis with the TCGA and CPTAC databases revealed that the mRNA and protein expression levels of <i>RBP7</i> in normal were higher compared to breast cancer tissues. Survival analysis displayed that the lower expression of <i>RBP7,</i> the worse the prognosis in ER-positive (ER<sup>+</sup>) breast cancer patients. Genomic analysis showed that low expression of <i>RBP7</i> correlates with its promoter hypermethylation in breast cancer. Functional enrichment analysis demonstrated that downregulation of <i>RBP7</i> expression may exert its biological influence on breast cancer through the PPAR pathway and the PI3K/AKT pathway. In summary, we identified <i>RBP7</i> as a novel biomarker that is helpful for the prognosis of ER<sup>+</sup> breast cancer patients. Promoter methylation of <i>RBP7</i> is involved in its gene silencing in breast cancer, thus regulating the occurrence and development of ER<sup>+</sup> breast cancer through the PPAR and PI3K/AKT pathways.

Journal

Journal of OncologyHindawi Publishing Corporation

Published: Oct 13, 2022

There are no references for this article.